Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
4.55
-0.03 (-0.66%)
At close: Aug 21, 2025, 3:59 PM
4.57
0.44%
After-hours: Aug 21, 2025, 04:10 PM EDT
-0.66% (1D)
| Bid | 4.38 |
| Market Cap | 7.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.25B |
| EPS (ttm) | -10.57 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | -1.05 |
| Analyst | Strong Buy |
| Ask | 4.66 |
| Volume | 31,537 |
| Avg. Volume (20D) | 332,322 |
| Open | 4.52 |
| Previous Close | 4.58 |
| Day's Range | 4.40 - 4.57 |
| 52-Week Range | 3.80 - 47.80 |
| Beta | -1.26 |
About ACXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-12.25%
Acurx Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
2 months ago
+167.26%
Acurx Pharmaceuticals shares are trading higher after the company announced publication of its Phase 2 ibezapolstat study results in The Lancet.
